Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity

Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity in Thoracic Malignancies

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00178230

Enrollment

Registered

2005-09-15

Start date

1996-03-15

Completion date

2013-11-25

Last updated

2017-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Brief summary

This study is being conducted by the University of Rochester Cancer Center to determine the levels of cytokines in the blood, and to determine if blood levels of these cytokines are related to the side effects of radiation therapy combined with other treatments.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients receiving radiation therapy for lung cancer combined with surgery either pre or post RT to the chest for lung cancer not associated with atelectasis, pleural effusion. Patients receiving HDR Brachytherapy for lung cancer. Patients receiving concomitant radiation and interferon therapy for lung cancer. Patients receiving concomitant chemotherapy and radiation for lung cancer. Prior drug therapy does not make patients ineligible. Karnofsky ≥ 70 %. There are no age restrictions. Acceptable bone marrow function - WBC 2 3000/mm3, platelet count \> 100,000, hematocrit ≥ 33%, hemoglobin ≥ 11 gms/dl. Life expectancy \> 6 months. Patients must sign informed consent meeting all federal and institutional guidelines.

Exclusion criteria

Patients not meeting eligibility criteria stated above

Countries

United States

Outcome results